SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing downward pressure, sparking debates about a potential bear market and the influence of large traders. Community discussions range from disbelief and panic selling to calls for holding and buying the dip, with some pointing to historical cycles and technical indicators. The overall sentiment is mixed as participants grapple with the current volatility and speculate about future price movements.

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Seres Therapeutics Inc

Seres Therapeutics is trending amid speculation about a potential acquisition, particularly following news of executive shifts and a rumored offer from Nestle. The community is weighing the possibility of a buyout versus a partnership, with some emphasizing the company's strategic value in microbiome therapeutics. Discussions also involve the potential impact of a lawsuit and the recent earnings call.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media ($DJT) is trending amidst discussions around its financial performance and broader political implications. Community members are debating the stock's valuation, potential delisting, and its ties to former President Trump's policies and public image. The stock's performance is being viewed by some as a referendum on the Trump brand and its future prospects.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros is trending as investors discuss the potential FDA approval of Narsoplimab by late December and its commercialization under the brand name Yartemlea. Community members are weighing the possibility of both adult and pediatric label approvals. Bullish sentiment is fueled by confidence in the drug's efficacy and anticipation of the Novo Nordisk deal closing, while some express caution, pointing to past setbacks and short interest.

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chun Sing Chan on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

Click Holdings ($CLIK) is trending due to strong revenue growth and speculation of a potential short squeeze, fueled by its low float and high insider ownership. Some traders are comparing it to other Hong Kong stocks that have experienced parabolic runs. Others warn about its history of volatility.

Alpha Technology Group Ltd. is a holding company, which engages in the provision of cloud-based IT solution service. The company was founded by Leung Tsz Him on October 5, 2022 and is headquartered in Hong Kong.

Alpha Technology Group Ltd - Ordinary Shares - Class A

ALPHA TECHNOLOGY GROUP LTD

ATGL is seeing volatile trading, with community members debating whether it's a pump and dump. Some traders point to the stock's low liquidity and potential for halts, while others highlight the possibility of a significant run. Discussions also include comparisons to other Hong Kong-based stocks and mentions of potential SEC scrutiny.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is seeing significant volatility as traders react to Fed commentary and broader market uncertainty, with community members actively discussing potential rate cuts and their impact. Bearish sentiment appears to be gaining traction, while dip buyers are getting crushed, leading to heightened discussion around potential support levels. Nvidia's upcoming earnings are also a key focal point, with many believing its performance could dictate the market's short-term direction.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending negatively as the stock hits new all-time lows, fueled by concerns over cash flow and a recent convertible note offering; the community is expressing frustration with the company's leadership and questioning the long-term viability of the stock, with some speculating about a potential take-private scenario or bankruptcy; investors are closely watching for any news or catalysts that could reverse the downward trend.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as traders monitor market volatility amidst economic uncertainty and anticipation of potential market downturns. Community discussions revolve around strategic short-term plays, reactions to market fluctuations, and the impact of macroeconomic factors like government shutdowns and tariff disputes. Concerns about AI, debt, and potential economic instability are fueling speculation and trading strategies around this volatility-linked ETF.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

SGML is trending as traders debate its short-term direction, with many pointing to "fake green candles" and anticipating further declines, especially after 11 am. Community chatter focuses on whether the stock will retest resistance levels or continue its downward trend amid high trading volume and a wide trading range. The discussion also includes perspectives on its valuation compared to peers in the lithium sector and speculation about potential catalysts.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$IFRX interesting link from Staidson BDB-001 (IFRX-1) - did not know that they started a phase I/II study 3 weeks ago in HS
A Multicenter, Randomized, Double-blind, Placebo Parallel-controlled, Phase I/II Study to Explore Safety and Efficacy of BDB-001 Injection in Subjects With Moderate to Severe Hidradenitis Suppurativa
https://drugsheet.com/?time=Past+Month&amp;phase=2&amp;intervention=BDB-001

John K.

CIELO1

Paul Stevenson

aecids

paradigman

Ivan

Drugsheet

StockTwits For Android 

InflaRx N.V.

 interesting link from Staidson BDB-001 (IFRX-1) - did not know that they started a phase I/II study 3 weeks ago in HS
A Multicenter, Randomized, Double-blind, Placebo Parallel-controlled, Phase I/II Study to Explore Safety and Efficacy of BDB-001 Injection in Subjects With Moderate to Severe Hidradenitis Suppurativa


@lichily Yes, here are the official links:
 
https://clinicaltrials.gov/ct2/show/NCT05093855?term=bdb-001&amp;draw=2&amp;rank=4
 
https://clinicaltrials.gov/ct2/show/NCT05103423?term=bdb-001&amp;draw=2&amp;rank=6
 
I suspect it has something to do with Lina Ma&#39;s resignation:
 
https://www.sec.gov/Archives/edgar/data/1708688/000114036121031347/brhc10028984_6k.htm
 
Remember: InflaRx has all global rights outside China to any and all discoveries derived from the development of BDB-001 in China.

Kevin

Primary Outcome Measures : Changes in INAPP (Inflammatory Nodules, Abscesses, Pyorrhea, Pain VAS) score relative to baseline [ Time Frame: Week 8 ] INAPP Score=(Inflammatory Nodule Count) + (Abscess Count*2) + (Pyorrhea *2)+（Pain VAS).The higher the score the more severe is the disease/worse is the outcome.

Clinicaltrials

Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) - Full Text View - ClinicalTrials.gov

Primary Outcome Measures : Number of participants with treatment-related adverse events as assessed by CTCAE v5.0. [ Time Frame: Week 8 ] Safety and tolerability of BDB-001 injection after multiple administration in the treatment of HS patients. Number of Participants developing anti-BDB-001 antibodies.

Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) - Full Text View - ClinicalTrials.gov

SECURITIES AND EXCHANGE COMMISSION REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2021 Commission File Number: 001-38283 (Translation of registrant's name into English) (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

StockTwits for iOS


 
I suspect it has something to do with Lina Ma's resignation:
 



 
Remember: InflaRx has all global rights outside China to any and all discoveries derived from the development of BDB-001 in China.

@Lexy911  excellent - thank you! BTW do you remember if there are any potential royalties for InflaRx on BDB-001 sales in China?

  excellent - thank you! BTW do you remember if there are any potential royalties for InflaRx on BDB-001 sales in China?

@lichily BDB shall be granted appropriate usage rights under InflaRx Intellectual Property to the extent necessary for development, manufacture and Commercialization of BDB-1 and BDB-2 solely inside the BDB Territory and pay in return royalties to INFLARX as set forth in this Agreement.

Please also read paragraph 7.8.

https://www.sec.gov/Archives/edgar/data/1708688/000095010317010902/dp82624_ex1003.htm

Jana Klar

INFLARX - BDB contract - confidential information page 1 of 33 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. [*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMMITTED MATERIAL HAS BEEN FILED SEPERATELY WITH THE COMMISSION.

 BDB shall be granted appropriate usage rights under InflaRx Intellectual Property to the extent necessary for development, manufacture and Commercialization of BDB-1 and BDB-2 solely inside the BDB Territory and pay in return royalties to INFLARX as set forth in this Agreement.

Please also read paragraph 7.8.



@Lexy911 that&#39;s fantastic - thanks for the details!

 that's fantastic - thanks for the details!